LOT DOCUMENTATION
Every report, by lot.
Third-party Certificates of Analysis are published here for each lot as they are issued. A product listing or image is not evidence of testing; only a report for your specific lot is.
PUBLISHED REPORTS · 5
- MOTS-c · 40 mgLOT MTSC-4001October 23, 2026Vanguard LaboratoryVIEW →
- Retatrutide · 18.5 mgLOT R3-2002October 23, 2026Vanguard LaboratoryVIEW →
- BPC-157 / TB-4 / GHK-Cu / KPV Complex · 80 mgLOT KR-8001October 23, 2026Vanguard LaboratoryVIEW →
- Tirzepatide · 18 mgLOT TRZ-2001October 23, 2026Vanguard LaboratoryVIEW →
- Retatrutide · 20 mgLOT 2001September 9, 2026Vanguard LaboratoryVIEW →
Not seeing your lot? Ask us about it with the compound name and exact lot number. A missing online report is not a passing or failing result.
BY SKU · 13
- GLP3R-020GLP-3R — Retatrutide · 20 mg2 REPORTS
- GLP3R-060GLP-3R — Retatrutide · 60 mgPENDING
- GLP2T-010GLP-2T — Tirzepatide · 10 mgPENDING
- GLP2T-020GLP-2T — Tirzepatide · 20 mg1 REPORT
- GLP2T-060GLP-2T — Tirzepatide · 60 mgPENDING
- MTSC-040MOTS-C · 40 mg1 REPORT
- RBK-080Research Blend K — formerly KLOW · 80 mg1 REPORT
- RBW-020Research Blend W — formerly Wolverine · 20 mgPENDING
- SEL-010Selank · 10 mgPENDING
- SEM-010Semax · 10 mgPENDING
- TESA-010Tesamorelin · 10 mgPENDING
- TESA-020Tesamorelin · 20 mgPENDING
- TESA-IPA-008-002Tesamorelin + Ipamorelin · 8 mg / 2 mgPENDING
Read the scope of each report.
- Match the compound, lot identifier, and sampled material to the material being considered.
- Check the report issuer, testing date, methods, results, and any stated limitations.
- Distinguish supplier documentation from testing performed by another laboratory. Neither should be assumed to exist without the relevant report.
- A chromatographic purity result alone does not establish identity, vial content, sterility, or suitability for a particular use.